Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Michael Garshick, MD, director of the cardio-rheumatology program, cardiologist and assistant professor, Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, explains the role of inflammation in coronary disease development and how this risk factor can be detected and treated.

Targeting coronary inflammation helps cardiologists provide better care

Michael Garshick, MD, examines the role of inflammation in coronary disease development, detailing how this risk factor can be detected and treated.

AI-powered risk score predicts how heart failure patients will respond to loop diuretics

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

Preventing blood clots after TMVR—what is the best anticoagulant for the job?

Choosing between DOACs and VKAs could make a significant impact on patient outcomes, according to new findings published in the Journal of the American College of Cardiology.

cardiologist preparing to perform radiofrequency ablation

Colchicine after AFib ablation fails to reduce risk of arrhythmia recurrence

However, the popular anti-inflammatory drug was linked to at least one other clinical benefit cardiologists should know about.

doctor with overweight patient who may be treated with TAVR or surgery

Are GLP-1 agonists safe? FDA finds no evidence popular weight loss medications cause suicidal thoughts or actions

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.

Imaging specialists partner with Pfizer to deliver AI-powered cardiac amyloidosis evaluations

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease.

Eli Lilly and Company launches online marketplace with home delivery to combat ‘complex’ healthcare system

The news comes as more and more medications, including Lilly's own tirzepatide, are being used to treat both obesity and diabetes.

‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes